United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027

Loading news article.

United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027 | WAPE

United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027

Article summary

Related companies

Comments —